成纤维细胞静脉注射途径实施血友病B基因治疗的初步探索

将转有报告基因ｌａｃＺ的成纤维细胞３Ｔ３／ＢＡＧ以５×１０＾５量尾静脉注射到Ｂａｌｂ／ｃ小鼠体内，７ｄ后在主要脏器检测到３ＴＥ／ＢＡＧ的表达且至少可持续３０ｄ。将转有人凝血因子Ⅸ小基因的正向表达载体Ｇ１ＮａＣｉ’Ⅸ和反向表达载体Ｇ１ＮａＣｉ’ⅨＲ的成纤维细胞ＰＡ３１７／Ｇ１ＮａＣｉ’Ⅸ和ＰＡ３１７／Ｇ１ＮａＣｉ’ⅨＲ分别以１×１０＾５量尾静脉注射到Ｂａｌｂ／ｃ小鼠体内，ＥＬＩＳＡ测定小鼠血浆中ｈＦ     

血友病B基因治疗临床试验的安全性研究

报道了血友病Ｂ基因治疗临床Ｉ期试验的安全性研究，包括反转录病毒基因的ＤＮＡ聚合酶反应（ＰＣＲ）、反转录ＰＣＲ（ＲＴ／ＰＣＲ）、Ｓｏｕｔｈｅｍ杂交以及ｎｅｏ基因和ｌａｃＺ基因的补求分析（ｒｅｓｏｕｅａｓｓａｙ）．从ＤＮＡ水平，ＲＮＡ水平和病毒活性体水平对野生型病毒进行了检测，没有检测到反转录病毒，并对兔和人转基因细胞进行形态学观察，染色体核型分析，软琼脂实验，裸鼠接种实验，兔和裸鼠的病理检测及电镜分     

血友病B基因治疗进展

血友病B是一种严重的凝血功能缺陷遗传病，由于现行的治疗方法对血友病B的治疗效果均不令人满意。因此，有必要开展血友病的基因治疗研究。本文介绍了血友病B的发病机理以及以反转录病毒载体为工具进行血友病B基因治疗的研究进展。     

肌细胞途径血友病B基因治疗的载体优化研究

构建了含有ＭＣＫ增强子,βａｃｔｕｎ启动子,及ｈＦＩＸ内含子１的３个载体Ｇ１ＮａＭＢＡＩＸ,Ｇ１ＮａＭＢＡｉＩＸ,Ｇ１ＮａＰＡＩＸｉ‘ＢＡＭ。转入ＰＡ３１７和成肌细胞Ｃ２Ｃ１２细胞后测定ｈＦＩＸ的表达,发现反向构建的Ｇ１ＮａＰＡＩＸｉ’ＢＡＭ表达最高且最稳定,而正向构建的Ｇ１ＮａＭＢａＩｉｘ的内含子常被剪切,在Ｃ２Ｃ１２细胞中表达不高。     

Expression of human clotting factor Ⅸ mediated by recom- binant lentiviral vector in cultured cells and hemophilia B mice

To explore the expression of human clotting factor Ⅸ (hFⅨ) cDNA in vitro and the feasibility of gene therapy for hemophilia B mice mediated by recombinant lentiviral vector, a recombinant hFⅨ lentiviral vector driven by ubiquitin-C promoter, FUXW, and by ABP liver specific promoter, FAXW, was constructed respectively. Recombinant lentivirus was harvested from 293T cells by calcium phosphate-mediated transient cotransfection of three plasmids (transgene vector, CMV腞8.2, VSV-G). hFⅨ expression was detected in supernatant of 293T, BHK and L-02 cells infected with FUXW virus, whereas higher expression of hFⅨ levels (630 ng/106 cells/48 h) was detected only in L-02 cells infected with FAXW virus. Serum hFⅨ antigen was detected in all hemophilia B mice treated with FAXW virus by tail vein injection, an efficiency level of hFⅨ was observed (45 ng/mL, approximately 1% of normal human levels), the expression lasted for more than 60 d. The results indicated that HIV-based lentiviral vectors offer a promising approach to the gene therapy of hemophilia B.     

AAV介导的TNFR关节内基因治疗对血友病性关节病预防和治疗的实验研究

血友病性关节病（HA）的发病机制与关节内炎性细胞因子过表达有关,肿瘤坏死因子α(TNFα)是最重要的炎性因子之一。可溶性肿瘤坏死因子受体(sTNFR)作为TNFα的受体可以特异性地与TNFα结合拮抗TNFα炎性效应。为探讨关节腔内持续表达sTNFR对HA关节的保护作用,将表达TNFR的质粒(pAAV-TNFR:Fc)包装为rAAV5-TNFR:Fc载体,注射到血友病小鼠膝关节内。结果显示炎症持续42 d后,关节内仍能表达TNFR:Fc,两个给药组中TNFα和白介素-1β(IL-1β)的表达不同程度地下降,关节病变均显著减轻,表明该关节内基因治疗对血友病性关节病有预防和治疗效果。     

凝血因子IX的体外检测方法研究

凝血因子ＩＸ的检测是血友病Ｂ基因治疗研究中的重要工作，在实验室原有基础上，发现和完善了凝血因子ＩＸ在蛋白质水平上的检测系统，为基因治疗血友病Ｂ提供了更为直观可靠的依据。首先，建立了以鼠抗人ＦＩＸ单克隆抗体Ａ－７为一抗的检测活性ＦＩＸ蛋白量的ＥＬＩＳＡ法，为检测活性ＦＩＸ提供了快速简便的方法。其次，实现了用Ｗｅｓｔｅｒｎｂｌｏｔ法检测转染细胞培养液上清中ＦＩＸ，确证了体外培养的转有人ＦＩＸｃＤＮＡ细     

Expression of human clotting factor Ⅸ mediated by recom- binant lentiviral vector in cultured cells and hemophilia B mice

Hemophilia B, a serious bleeding disorder, is an inherited X chromosome-linked disease for the deficiency or inactivity of human clotting factor Ⅸ (hFⅨ). Though factor substitution therapy has greatly improved the lives of hemophiliac patients, there are still limitations to the current treatment, which have triggered interest in alternative treatments by gene therapy[1]. Based on preclinical studies in rabbits[2], our lab had first initiated an ex vivo gene therapy clinical trial whereby a…     

慢病毒载体及其介导的RNA干扰在基因治疗中的应用研究

主要就慢病毒载体及其介导的RNA干扰技术在基因治疗中的应用研究进行了综述,并对其在该领域具有的广阔前景进行了展望.慢病毒载体作为一种新型的载体,可有效地将携带的目的基因导入宿主细胞,并将其整合到宿主细胞基因组中,从而使目的基因得以持久稳定地表达.该载体因具有高感染性、高表达效率及不易诱发宿主免疫反应等优点,已成为基因治疗研究中的一个重要工具.RNA干扰技术可以特异性抑制或关闭特定基因的表达,因此该技术可广泛应用在基因功能探究和恶性肿瘤治疗等领域.由慢病毒载体介导的RNA干扰技术能持久、稳定、特异性地抑制各类细胞中特定基因的表达,在病毒感染、肿瘤等疾病的基因治疗中被广泛应用,成为生物医学领域的新热点.     

Construction and expression of inverted configuration of retroviral vector containing intron 1 of hFIX

Intron was found to play an important role in improving gene expression. To improve the human factor IX(hFIX) expression level in hemophilia B gene therapy study, the retroviral vector containing intron 1 of hFIX gene was constructed in forwarded configuration, but the intron 1 was found spliced in virus particles by RT_PCR detection. So the inverted configuration vector G1NaPAi′IX was suggested and constructed on the basis of SNMBAIXm and transfected into PA317. Then C2C12 cells were transfected using the above virus supernatant and the G418_resistant clones were selected. PCR and RT_PCR detection found that intron 1 structure existed in C2C12 clones and retroviral particles. And the expression level of inverted vector was 3 times higher than that of forwarded vector. These results showed that the inverted configuration vector was in deed able to avoid splicing of intron 1 during the process of retroviral packaging and improved the expression level of hFIX protein.     

新型Bola两亲分子作为基因治疗药物输递载体的研究

为检测新型Bola两亲分子(Orn-C16-G)用作基因载体的性能,制备了Bola与siRNA的复合物(Bolaplexes),用原子力显微镜观察其在不同复合比下的形貌;并转染Hela细胞,用CCK-8检测Bolaplexes的细胞毒性,用荧光显微镜、流式细胞仪表征Bolaplexes的细胞内吞效果。实验结果显示,复合比1∶1条件下,Bola分子可以有效地压缩siRNA分子形成较小尺寸的复合物(100～200 nm)。Bolaplexes可高效地进入Hela细胞,并且毒性低于商售转染试剂,有较好的应用前景。本研究为下一步Bola两亲分子用于基因治疗的临床研究奠定了基础。     

运用HSV－tk／ACV系统进行肿瘤基因治疗研究

构建了含ｐｇｋ启动子驱动的ＨＳＶ－ｔｋ基因的反转录病毒载体ｐＬＮＴＫ，将ＨＳＶ－ｔｋ基因转移至人脑胶质瘤ＳＨＧ４４细胞（命名为ＳＨＧＬＮＴＫ）及小鼠黑色素瘤细胞Ｂ１６（命名为Ｂ１６ＬＮＴＫ）．体外实验证实核着类似物ＡＣＶ对ＳＨＧＬＮＴＫ细胞和Ｂ１６ＬＮＴＫ细胞的杀伤敏感性分别高于亲本细胞１０００和４００倍．转ＨＳＶ－ｔｋ基因细胞与亲本细胞按不同比例共培养时，亲本细胞对ＡＣＶ的敏感性明显增高，存在旁观者效应．首次应用人脑胶质瘤细胞株进行裸鼠体内实验，结果表明：ＡＣＶ能完全抑制ＳＨＧＬＮＴＫ细胞在裸小鼠体内肿瘤的形成，对裸小鼠体内已形成的ＳＨＧＬＮＴＫ肿瘤的治疗效果与对照ＳＨＧ４４肿瘤相比，肿瘤体积缩小８０％；用Ｂ１６ＬＮＴＫ细胞接种同系Ｃ５７／ＢＬ小鼠，经ＡＣＶ治疗后，Ｂ１６ＬＮＴＫ组小鼠的肿瘤较对照组Ｂ１６肿瘤小９５％．ＨＳＶ－ＴＫ／ＡＣＶ系统原位基因转移治疗ＳＨＧ荷瘤裸小鼠、Ｂ１６荷瘤小鼠，原位注射病毒悬液／ＡＣＶ治疗组的ＳＨＧ肿瘤、Ｂ１６肿瘤分别较对照组肿瘤小５０％，４３％，原位注射ＰＡ３１７／ＬＮＴＫ细胞，ＡＣＶ治疗的ＳＨＧ肿瘤较对照组肿瘤小９０％，以上实验结果，统计学上差异极显著，Ｐ＜０．０１．实验